FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
08/11/2024
Back to search
Official data from USPTO
MOGANSHAN
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
36
Latest update
08/11/2024
Classification
Registered
Trademark type
Combined
Nice classes
5
Filing date
06/14/2022
Registration date
03/19/2024
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/19/2024
Last transaction
03/19/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
99
Owner location
CN
Examiner
WOOD, DANIEL
Law office
O10
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of a circle surrounding stylized clouds, bamboo trees, and mountains. Below the circle are Chinese characters above the wording "MOGANSHAN" in stylized text.
Holders and representatives
Holders
Zhejiang Zhebei Pharmaceutical Co., Ltd.
Representatives
Prakash NAMA Global IP Services, PLLC
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Drugs for medical purposesadjuvant treatment of myocardial ischemiashockhypoxiatissue damage; Drugs for medical purposesantivirals for the treatment of acute zosterincipient and recurrent genital herpeschickenpox; Drugs for medical purposesantivirals suitable for treating viral pneumonia caused by respiratory syncytial virusbronchitisskin herpes virus infectionin combination with interferon alpha for the treatment of chronic hepatitis C in adults; Drugs for medical purposesanticancer preparations for choriocarcinomamalignant moleacute lymphoblastic leukemia and acute non-lymphoblastic leukemiaacute stage of chronic granulocytic leukemia; Drugs for medical purposesantiallergic medicine for the treatment of seasonal rhinitisperennial allergic rhinitisallergic conjunctivitis and allergy-induced pruritus and urticaria; Antibiotics; Drugs for medical purposesadjuvant treatment of acute and chronic hepatitis; Pharmaceutical preparationsadjuvant treatment of myocardial ischemiashockhypoxiatissue damage; Pharmaceutical preparationsantivirals for the treatment of acute zosterincipient and recurrent genital herpeschickenpox; Pharmaceutical preparationsantivirals suitable for treating viral pneumonia caused by respiratory syncytial virusbronchitisskin herpes virus infectionin combination with interferon alpha for the treatment of chronic hepatitis C in adults; Pharmaceutical preparationsanticancer for choriocarcinomamalignant moleacute lymphoblastic leukemia and acute non-lymphoblastic leukemiaacute stage of chronic granulocytic leukemia; Pharmaceutical preparationsantiallergic medicine for the treatment of seasonal rhinitisperennial allergic rhinitisallergic conjunctivitis and allergy-induced pruritus and urticaria; Pharmaceutical preparationsadjuvant treatment of acute and chronic hepatitis; Antivirals suitable for treating viral pneumonia caused by respiratory syncytial virusbronchitisskin herpes virus infection in combination with interferon alpha for the treatment of chronic hepatitis C in adults; Antiallergic medicine for the treatment of seasonal rhinitisperennial allergic rhinitisallergic conjunctivitis and allergy-induced pruritus and urticaria; Antivirals for the treatment of acute zosterincipient and recurrent genital herpeschickenpox; Anticancer preparations for choriocarcinomamalignant moleacute lymphoblastic leukemia and acute non-lymphoblastic leukemiaacute stage of chronic granulocytic leukemia
Publications
History of USPTO decisions and trademark events.
36 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
07/21/2024
FIMP
FINAL DISPOSITION PROCESSED
07/21/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
06/20/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
03/19/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
03/19/2024
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
01/07/2024
GPNX
NOTIFICATION PROCESSED BY IB
01/02/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/02/2024
PUBO
PUBLISHED FOR OPPOSITION
01/02/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
12/20/2023
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
12/20/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
12/13/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
12/13/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/13/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/22/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
11/16/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
11/16/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
11/16/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
11/16/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
11/10/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
11/10/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
11/10/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
11/10/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/26/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/26/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/26/2023
RFNT
REFUSAL PROCESSED BY IB
06/18/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
05/31/2023
RFRR
REFUSAL PROCESSED BY MPU
05/31/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
04/01/2023
CNRT
NON-FINAL ACTION WRITTEN
03/31/2023
DOCK
ASSIGNED TO EXAMINER
03/27/2023
MAFR
APPLICATION FILING RECEIPT MAILED
07/19/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/15/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
07/14/2022
Continuous trademark protection
Get notified about every new filing that threatens MOGANSHAN or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.